Pharmacological Treatment of Hearing Loss

Dear Colleagues,

Hearing loss is recognized as a serious health problem, especially in the generic population, but also in the industrialized environment, where the level of noise can increase hearing loss among children, young, and middle-aged people. To date, there is no widely used pharmacological treatment officially approved by the FDA (Food and Drug Administration) or EMA (European Medical Agency). The prevention of death of hearing cells can be incredibly challenging. For people with severe to profound hearing loss, cochlear implants are the only option, while for less severe cases, hearing aids are possible. As a result, questions about possible, effective, and safe pharmacological treatment are still open.

This Special Issue o ‘Pharmacological Treatment of Hearing Loss’ aims to focus on major developments related to the pharmacological and biological treatment of hearing loss and possible mechanisms (pharmacological approaches of prevention of hearing loss caused by exposure to moderate levels of noise in the workplace (e.g., machinery), recreational environments (e.g., loud music, motorcycles), drug, age-related hearing loss, ototoxic agents, and many other factors.

Papers discussing the results of basic and clinical research will be accepted, as well as review papers. Possible topics include both pharmacological treatments and other technical or hybrid solutions.

Dr. Magdalena B. Skarżyńska
Prof. Dr. Piotr Henryk Skarżyński
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.